<SEC-DOCUMENT>0001213900-23-074136.txt : 20230906
<SEC-HEADER>0001213900-23-074136.hdr.sgml : 20230906
<ACCEPTANCE-DATETIME>20230906070025
ACCESSION NUMBER:		0001213900-23-074136
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230906
FILED AS OF DATE:		20230906
DATE AS OF CHANGE:		20230906

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tiziana Life Sciences Ltd
		CENTRAL INDEX KEY:			0001723069
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			D0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38723
		FILM NUMBER:		231237828

	BUSINESS ADDRESS:	
		STREET 1:		3RD FLOOR, 11-12 ST. JAMES'S SQUARE
		CITY:			LONDON, ENGLAND
		STATE:			X0
		ZIP:			SW1Y 4LB
		BUSINESS PHONE:		0044(0) 207-495-2379

	MAIL ADDRESS:	
		STREET 1:		3RD FLOOR, 11-12 ST. JAMES'S SQUARE
		CITY:			LONDON, ENGLAND
		STATE:			X0
		ZIP:			SW1Y 4LB

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tiziana Life Sciences plc
		DATE OF NAME CHANGE:	20171116
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea184749-6k_tiziana.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>FORM&nbsp;6-K</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>September 2023</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P> <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number:</B>&nbsp; <B>001-38723</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P> <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Tiziana Life
Sciences LTD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in Its Charter)</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P> <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>9<SUP>th</SUP>&nbsp;Floor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>107 Cheapside</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>London
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>EC2V 6DN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of registrant&rsquo;s principal executive
office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form&nbsp;20-F or Form&nbsp;40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form&nbsp;20-F&nbsp;&#9746;&nbsp;Form&nbsp;40-F
&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION CONTAINED IN THIS REPORT ON FORM&nbsp;6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 6, 2023, Tiziana Life Sciences LTD (the &ldquo;<U>Company</U>&rdquo;)
issued a press release, announcing the acceptance of a publication, &ldquo;Nasal Administration of anti-CD3 monoclonal antibody (mAb)
ameliorates disease in a mouse model of Alzheimer&rsquo;s disease&rdquo;, in the preeminent journal, Proceedings of the National Academy
of Sciences (PNAS), that supports foralumab&rsquo;s mechanism as a potential treatment for Alzheimer&rsquo;s disease (AD), a difficult-to-treat
neuroinflammatory disease. This is the second publication pertaining to intranasal administration of anti-CD3 monoclonal antibody this
year to be published in PNAS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Announcement is furnished herewith as Exhibit
99.1 to this Report on Form&nbsp;6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed &ldquo;filed&rdquo;
for the purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor
shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities
Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TIZIANA LIFE SCIENCES LTD</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 31%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Date: September 6, 2023</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Keeren Shah</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Keeren Shah</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 90%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="ea184749ex99-1_tiziana.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">News Service Announcement, dated September 6, 2023</FONT></A></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea184749ex99-1_tiziana.htm
<DESCRIPTION>NEWS SERVICE ANNOUNCEMENT, DATED SEPTEMBER 6, 2023
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><FONT STYLE="font-size: 12pt">Study Validating
MoA of Intranasal Foralumab in Alzheimer&rsquo;s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; background-color: #FEFEFE">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>The authors conclude that &ldquo;nasal anti-CD3 has the potential to be
a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer&rsquo;s disease (AD)&rdquo;</B></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>FDA has cleared the IND for intranasal foralumab, a fully human anti-CD3
monoclonal antibody, for human study in mild to moderate Alzheimer&rsquo;s Disease</B></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>The publication shows anti-CD3 monoclonal antibody (mAb) administered
intranasally, ameliorates disease in a 3xTg model of Alzheimer&rsquo;s disease by targeting microglial activation in the brain, while
expanding regulatory T cells in the periphery</B></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Remarkably, this reduced microglial activation and improved cognition
occurs independent of amyloid beta disposition.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">NEW YORK,&nbsp;September 6, 2023 -- Tiziana
Life Sciences Ltd.&nbsp;(Nasdaq: TLSA) (&ldquo;Tiziana&rdquo; or the &ldquo;Company&rdquo;), a biotechnology company developing breakthrough
immunomodulation therapies via novel routes of drug delivery, today announced acceptance of a publication, &ldquo;Nasal Administration
of anti-CD3 monoclonal antibody (mAb) ameliorates disease in a mouse model of Alzheimer&rsquo;s disease&rdquo;, in the preeminent<SUP>1</SUP>
journal, <I>Proceedings of the National Academy of Sciences</I> (PNAS), that supports foralumab&rsquo;s mechanism as a potential treatment
for Alzheimer&rsquo;s disease (AD), a difficult-to-treat neuroinflammatory disease.<SUP>2</SUP> This is the second publication pertaining
to intranasal administration of anti-CD3 monoclonal antibody this year to be published in PNAS.<SUP>3</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">This study shows that intranasal anti-CD3
ameliorates disease in a rodent model of AD by targeting microglial activation in the brain and brain gene expression independent of affecting
amyloid beta deposition. These studies identify a novel approach to treat Alzheimer&rsquo;s disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT></TD><TD STYLE="text-align: justify">https://www.pnas.org/about/article-journal-metrics</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2</SUP></FONT></TD><TD STYLE="text-align: justify">https://www.pnas.org/doi/10.1073/pnas.2309221120</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><SUP>3</SUP></TD><TD STYLE="text-align: justify">https://www.pnas.org/doi/10.1073/pnas.2220272120</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">The publication can be found at : https://www.pnas.org/doi/10.1073/pnas.2309221120</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Howard L. Weiner, M.D., a Robert L. Kroc Professor of Neurology at
the&nbsp;Harvard Medical School, Director and Founder of the Partners Multiple Sclerosis Center and Co-Director of the&nbsp;Center for
Neurologic Diseases&nbsp;at Brigham and Women&rsquo;s Hospital, a founding member of&nbsp;Mass General Brigham Healthcare System and Chairman
of Tiziana&rsquo;s&nbsp;Scientific Advisory Board, stated, &ldquo;I am proud to be the senior author on this seminal publication showing that
anti-CD3 mAb mitigates Alzheimer&rsquo;s disease in a rodent model. Remarkably, we found this benefit occurred independent of reduction
of amyloid beta plaque in the brain. This finding demonstrates a unique mechanism of action that can now be tested in humans using foralumab,
a fully human anti-CD3 mAb, foralumab, in which we modulate microglia by inducing T cells in the periphery that migrate to the brain.
This represents a unique approach to treating Alzheimer&rsquo;s disease that could also potentially be employed in combination with anti-amyloid
therapy. The neuromodulation of the T cell inflammatory response we observed in the brains of Alzheimer&rsquo;s mice is consistent with
multiple sclerosis research we have conducted at the Ann Romney Center and validates our scientific rationale for testing foralumab in
Alzheimer&rsquo;s patients after the recent IND clearance by the United States Food and Drug Administration.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&ldquo;We&rsquo;ve now have had two seminal
publications in the esteemed journal <I>PNAS</I> related to novel and significant research on intranasal anti-CD3. It has been established
through both publications that intranasal anti-CD3 positively modulates the immune system allowing Tiziana to explore foralumab in multiple
neuro-inflammatory disease indications in addition to our ongoing research in non-active secondary progressive multiple sclerosis. We
believe this scientific publication, along with the groundbreaking research continuously being conducted by our partners at Brigham and
Women&rsquo;s Hospital led by Dr. Weiner, greatly increases the utilization potential of our foralumab portfolio,&rdquo; commented Gabriele
Cerrone, Executive Chairman, founder and acting Chief Executive Officer of Tiziana.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>Study Rationale</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">Alzheimer&rsquo;s disease is a neurodegenerative
disease characterized by amyloid beta (A&beta;) plaques, neurofibrillary tangles, and microglial activation. Neuroinflammation is a major
component of AD. Microglia are the primary immune cells of the brain that help both maintain homeostasis and react to injury. Studies
showing activated microglia and astrocytes surrounding A&beta; plaques suggest significant involvement of inflammatory pathways in Alzheimer&rsquo;s
disease. Therapies targeting A&beta; have shown positive effects in subjects with AD. Nasal anti-CD3 has been shown to treat animals with
a progressive form of experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis, by inducing regulatory T cells
that dampen microglial inflammation in the brain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>Study Design</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">In this study, mice were treated three times
a week with intranasal anti-CD3 for five months and compared against isotype control or saline. In the treated mice, the study found modulation
of the activated microglia phenotype, changes in gene expression patterns in the brain and improved cognition, which all occurred independent
of affecting amyloid beta deposition. Modulation of activated microglia was measured in treated mice by sorting the microglia using microglia-specific
markers and performing a gene expression analysis using the Nanostring mouse myeloid panel and comparing treated mice versus control.
Changes in gene expression were measured in the cortex and hippocampus. Cognition was measured including spatial learning and long- and
short- term memories as assessed by the Morris water maze and the novel arm Y-maze behavioral test. Amyloid beta accumulation was measured
by immunofluorescence in the hippocampus and prefrontal cortex areas of the brain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>About Foralumab</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">Activated T cells play an important role
in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T cell receptor and dampens
inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets, an effect demonstrated
in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects. Intranasal foralumab Phase 2 trials are expected
to start in Q3 2023 in patients with non-active SPMS immunomodulation by nasal anti-CD3 mAb represents a novel avenue for treatment of
inflammatory human diseases that affects the brain and other organs.<SUP>2,3</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>About&nbsp;Tiziana Life Sciences</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">Tiziana Life Sciences&nbsp;is a clinical-stage
biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes
of immunotherapy. Tiziana&rsquo;s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement
in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana&rsquo;s lead candidate, intranasal foralumab,
the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana&rsquo;s
technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad
pipeline applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">For further inquiries:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>Tiziana Life Sciences Ltd</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">Paul Spencer, Business Development and Investor
Relations<BR>
+44 (0) 207 495 2379<BR>
info@tizianalifesciences.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>Investors:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B></B>Irina Koffler<BR>
LifeSci Advisors, LLC<BR>
646.970.4681<BR>
<FONT STYLE="text-decoration: none">ikoffler@lifesciadvisors.com</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: #FEFEFE">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  B )8# 2(  A$! Q$!_\0
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M2EOHKF*^.H--?QV#Z6B6[:C-\!^'_P#@BA_P4H_83^(?QJOO^"1O_!13X?\
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M[>>)-6U75M3O+F*S12ON?XU_MJ^,_P!FO]H+XS?\-Q_M.:Q^Q+\%I_%R:/\
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2#Q-XALX+B.WUK4H[DHHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
